Subscribe to our mailing list

Nektar Therapeutics reportedly contemplating sale

Nektar Therapeutics is exploring choices together with a possible sale of the $15 billion biotechnology agency, in line with individuals with information of the matter.

The San Francisco firm may additionally go for partnerships and licensing agreements as an alternative of a disposal, stated the individuals, asking to not be recognized as a result of the discussions are personal.

Nektar has attracted curiosity from bigger drugmakers, although some potential suitors are cautious of a full takeover due to the excessive valuation and dangers associated to its pipeline of experimental medication, the individuals stated.

No remaining selections have been made and concerns could not result in a transaction, they stated.

Powered by WPeMatico

Author: Techno Info

VN:F [1.9.22_1171]
Rating: 0.0/10 (0 votes cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)

Author Spotlight